40 results
8-K
EX-99.1
ACGN
Aceragen Inc
5 Nov 09
Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update
12:00am
experienced stable disease.
Recruitment of additional patients is continuing at the anticipated recommended phase 2 dose level for IMO-2055 … in this combination.
Phase 1b Clinical Trial of IMO-2055 in Combination with Erbitux® and Camptosar® in Colorectal Cancer
Patient recruitment is ongoing
CORRESP
ACGN
Aceragen Inc
26 Sep 06
Correspondence with SEC
12:00am
] in these expenses in the nine months ended September 30, 2006 was primarily attributable to .
In October 2004, we commenced patient recruitment … to 46 treatment-naïve patients in Stage A, in addition to the 46 second-line patients provided for by the original study design. Recruitment has been
8-K
EX-99.1
ACGN
Aceragen Inc
6 Nov 18
Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
5:01pm
refractory/relapsed metastatic melanoma:
Ipilimumab Combination Arm — Phase 2 Recruitment Ongoing
· Enrollment continues at 10 U.S. clinical trial
CORRESP
ACGN
Aceragen Inc
30 Aug 06
Correspondence with SEC
12:00am
and overhead.
In October 2004, we commenced patient recruitment for an open label, multi-center Phase 2 clinical trial of IMO-2055 as monotherapy … study design. Recruitment has been slower than we projected, in part due to the clinical trial activities of other companies and the recent approval